Durgical
EN
Open the app

Living with sickle cell disease: prevention, hydroxyurea, transfusion and screening

  • Treatment and support

Many sickle cell deaths are preventable: newborn screening, penicillin, vaccines, hydroxyurea and a yearly brain scan in children change the whole course.

Updated

What it is

Long-term care in sickle cell disease aims to prevent the crises and the slow organ damage rather than only react to them. Its pillars are early diagnosis by newborn screening, protection against infection, disease-modifying treatment with hydroxyurea, transfusion for defined indications, regular screening for damage to the brain, kidneys, eyes, lungs and bones, and, for a few patients, cure by stem cell transplant or gene therapy.

What to know

  • Newborn screening allows penicillin prophylaxis and vaccination before the first infection; penicillin is given daily in early childhood, at least until about five years of age.
  • Vaccines: pneumococcal (conjugate and polysaccharide), Haemophilus influenzae type b, meningococcal and yearly influenza, on top of the routine schedule.
  • Hydroxyurea raises fetal haemoglobin, which does not polymerise; it reduces pain crises, acute chest syndrome, transfusions and hospital stays, and is offered from infancy to children with HbSS.
  • Transcranial Doppler ultrasound every year in children with HbSS (roughly from 2 to 16 years) detects fast flow in narrowed brain arteries; regular transfusion in those children greatly reduces first strokes.
  • Regular transfusion is used for stroke prevention (primary and after a stroke) and some severe complications; it brings iron overload and red cell antibodies.
  • Allogeneic stem cell transplant from a matched sibling can cure the disease; gene therapies have been approved in some countries.

How it is done (and why)

  1. Confirm the diagnosis by haemoglobin analysis from newborn screening or a later test, and teach the family the warning signs.
  2. Start penicillin prophylaxis in infancy and complete the extra vaccines; give a fever plan that sends the child to hospital at once.
  3. Offer hydroxyurea and monitor the blood count regularly, because it suppresses the marrow; adjust to effect.
  4. Screen children with transcranial Doppler every year; abnormal results lead to a regular transfusion programme.
  5. Check kidneys (urine albumin), eyes (retina), lungs and heart, hips and gallbladder at regular visits.
  6. Plan for transfusion with extended red cell matching (Rh and Kell), and chelation when iron accumulates.
  7. Discuss transplant or gene therapy at a specialist centre for patients with severe disease and a suitable donor.

What each measure prevents

MeasureWhat it preventsHow it worksWhat to watch
Penicillin and vaccinesPneumococcal and other encapsulated infectionsReplace the protection lost with the spleenAdherence; fever still means hospital
HydroxyureaPain crises, acute chest syndrome, transfusionsRaises fetal haemoglobin; fewer sticky white cellsBlood counts (low neutrophils, platelets); pregnancy plans
Transcranial DopplerFirst stroke in childrenFinds narrowed brain arteries before they blockYearly; abnormal results need transfusion
Regular transfusionStroke and its recurrence; some severe complicationsDilutes HbS and suppresses sickle cell productionIron overload, red cell antibodies
Transplant or gene therapyThe disease itselfReplaces or corrects the stem cellsSpecialist centres; donor and access

Risks and precautions

  • Hydroxyurea raises the MCV; a stable or falling MCV on treatment can be a sign the tablets are not being taken.
  • Hydroxyurea and pregnancy need planning: discuss contraception and review the treatment before and during pregnancy with the specialist.
  • Pregnancy in sickle cell disease is high risk for crises, thrombosis, pre-eclampsia and fetal growth problems and is followed jointly by obstetrics and haematology.
  • HbSC disease has milder anaemia but more retinopathy and avascular necrosis; it still needs screening.
  • Chronic pain, school and work absence and stigma are part of the disease; psychological and social support belongs in care.

Monitoring and next step

  • Baseline: haemoglobin analysis with HbF, full blood count and reticulocytes, extended red cell phenotype before any transfusion.
  • On hydroxyurea: blood count regularly to catch low neutrophils or platelets, and HbF and MCV to judge response.
  • Yearly: urine albumin, kidney and liver function, transcranial Doppler in children, and retinal examination from about ten years of age.
  • On regular transfusion: ferritin and, where available, MRI of liver iron; antibody screen before each transfusion.
  • New symptoms such as hip pain, breathlessness on exertion or leg ulcers: hip imaging, echocardiography or wound referral as appropriate.

Common traps

  • Reserving hydroxyurea for adults with many crises: it is offered early, to children, to prevent damage, not only to treat it.
  • Stopping penicillin or skipping vaccines because the child is well: the risk comes from the absent spleen, not from symptoms.
  • Transfusing without extended matching: patients on regular transfusion often make antibodies that make later blood hard to find.
  • Ignoring the normal-looking HbSC patient: retinopathy and bone necrosis can progress silently.

Test yourself

Think of the answer, then tap the question to see it.

How does hydroxyurea reduce sickling?

It raises fetal haemoglobin in red cells; HbF does not join HbS polymers, so cells sickle less and live longer. It also lowers white cells that make vessels sticky.

Why are children with HbSS screened yearly with transcranial Doppler, and what follows an abnormal result?

Fast flow marks narrowed brain arteries at high risk of a first stroke; a regular transfusion programme in those children greatly lowers that risk.

A teenager on hydroxyurea has an MCV that has fallen back to his old value. What should you ask about?

Whether he is taking it: hydroxyurea raises the MCV, so a return to baseline suggests poor adherence (or a new cause such as iron deficiency).

Why are patients with sickle cell disease given red cells matched for Rh and Kell antigens?

Repeated transfusion often triggers antibodies against these antigens, which cause delayed haemolytic reactions and make compatible blood hard to find.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Sickle Cell Anemia (StatPearls Publishing (NCBI Bookshelf), 2023); Hydroxyurea: MedlinePlus Drug Information (MedlinePlus, US National Library of Medicine, 2026); Newborn screening tests (MedlinePlus, US National Library of Medicine, 2026); Sickle cell disease: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.